Aligos Therapeutics, Inc. financial data

Symbol
ALGS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Corporate Dr., 2 Nd Floor, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 422 % +2.4%
Debt-to-equity 167 % +206%
Return On Equity -354 % -204%
Return On Assets -133 % -76.2%
Operating Margin -2.47K % -73.4%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 3.86M shares +28.6%
Entity Public Float 38.7M USD +91.6%
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 6.26M shares +144%
Weighted Average Number of Shares Outstanding, Diluted 6.26M shares +144%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 3.61M USD -41.7%
Research and Development Expense 70.3M USD -3.79%
General and Administrative Expense 22.8M USD -25.4%
Operating Income (Loss) -89.2M USD -1.17%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -131M USD -50.6%
Income Tax Expense (Benefit) 331K USD -58.4%
Net Income (Loss) Attributable to Parent -131M USD -49.6%
Earnings Per Share, Basic -20.9 USD/shares +38.8%
Earnings Per Share, Diluted -20.9 USD/shares +38.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37M USD -72.7%
Cash, Cash Equivalents, and Short-term Investments 56.9M USD -58.1%
Other Assets, Current 5.09M USD -4.11%
Assets, Current 62.1M USD -56%
Property, Plant and Equipment, Net 2.36M USD -27.5%
Operating Lease, Right-of-Use Asset 4.96M USD -24.3%
Other Assets, Noncurrent 627K USD +0.32%
Assets 70.1M USD -53.7%
Accounts Payable, Current 2.57M USD +2.15%
Employee-related Liabilities, Current 6.39M USD -4.29%
Accrued Liabilities, Current 15.6M USD -7.63%
Liabilities, Current 21.7M USD -9.07%
Operating Lease, Liability, Noncurrent 4.8M USD -37.5%
Liabilities 99.1M USD +66.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 451K USD -17.2%
Retained Earnings (Accumulated Deficit) -618M USD -27%
Stockholders' Equity Attributable to Parent -29M USD -131%
Liabilities and Equity 70.1M USD -53.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.7M USD -1.6%
Net Cash Provided by (Used in) Financing Activities -19K USD -1800%
Net Cash Provided by (Used in) Investing Activities -88.6M USD -543%
Common Stock, Shares Authorized 20.8M shares +62.5%
Common Stock, Shares, Issued 3.86M shares +28.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 37.1M USD -72.7%
Deferred Tax Assets, Valuation Allowance 56.5M USD +65.1%
Deferred Tax Assets, Gross 58.3M USD +59.2%
Operating Lease, Liability 8.22M USD -24.6%
Depreciation 1.03M USD -34.1%
Payments to Acquire Property, Plant, and Equipment 7K USD -98.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -131M USD -50%
Lessee, Operating Lease, Liability, to be Paid 9.05M USD -28.4%
Property, Plant and Equipment, Gross 14.1M USD +0.93%
Operating Lease, Liability, Current 3.42M USD +5.98%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.79M USD +3.04%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.67M USD +3.06%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 835K USD -52.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD -62.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 771K USD +679%
Lessee, Operating Lease, Liability, to be Paid, Year Four 155K USD -89.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.76M USD -26.1%
Share-based Payment Arrangement, Expense 8.45M USD -33.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%